146 related articles for article (PubMed ID: 4080)
1. Effects of the cardioselective beta-adrenergic receptor blocking agent metoprolol in angina pectoris. Subacute study with exercise tests.
Ekelund LG; Olsson AG; Orö L; Rössner S
Br Heart J; 1976 Feb; 38(2):155-61. PubMed ID: 4080
[TBL] [Abstract][Full Text] [Related]
2. Effects of the cardioselective beta-blocker metoprolol in angina pectoris. A subacute study with exercise tests.
Keyriläinen O; Uustialo A
Ann Clin Res; 1975 Dec; 7(6):433-41. PubMed ID: 2092
[TBL] [Abstract][Full Text] [Related]
3. Effects of metoprolol in angina pectoris. A subacute study with exercise tests and a long-term tolerability study.
Keyriläinen O; Uusitalo A
Acta Med Scand; 1976; 199(6):491-7. PubMed ID: 7100
[TBL] [Abstract][Full Text] [Related]
4. Assessment of metoprolol, a cardioselective beta-blocking agent, during chronic therapy in patients with angina pectoris.
Borer JS; Comerford MB; Sowton E
J Int Med Res; 1976; 4(1):15-22. PubMed ID: 799974
[TBL] [Abstract][Full Text] [Related]
5. Slow-release metoprolol in angina pectoris. A comparative study of a cardioselective beta-blocking drug, metoprolol, in ordinary and slow-release tablets (Durules) in the treatment of angina pectoris.
Uusitalo AJ; Keyriläinen O
Ann Clin Res; 1979 Oct; 11(5):199-204. PubMed ID: 44671
[TBL] [Abstract][Full Text] [Related]
6. Antianginal efficacy and improved exercise performance with timolol. Twice-daily beta blockade in ischemic heart disease.
Harris FJ; Low RI; Paumer L; Amsterdam EA; Mason DT
Am J Cardiol; 1983 Jan; 51(1):13-8. PubMed ID: 6129794
[TBL] [Abstract][Full Text] [Related]
7. Dose related efficacy of betaxolol in combination with nitroglycerin in patients with angina pectoris: a double blind cross-over study.
Stroobandt R; Kesteloot H
Arch Int Pharmacodyn Ther; 1984 Feb; 267(2):299-309. PubMed ID: 6143538
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of bisoprolol in patients with stable angina pectoris: a preliminary report.
Kato K; Niitani H; Kanazawa T; Shimomura K; Toyama S
J Cardiovasc Pharmacol; 1986; 8 Suppl 11():S154-9. PubMed ID: 2439788
[TBL] [Abstract][Full Text] [Related]
9. A double-blind trial of penbutolol: a new beta-receptor blocking agent in the treatment of angina pectoris.
Agarwal AK; Ahuja RC; Chandra M; Gupta NN; Hasan M
J Int Med Res; 1976; 4(6):410-7. PubMed ID: 17557
[TBL] [Abstract][Full Text] [Related]
10. The effects of a new adrenergic blocking agent (K4423) on exercise tolerance in angina pectoris.
Libretti A; Gregorini L; Valentini R
Cardiology; 1973; 58(6):369-75. PubMed ID: 4153721
[No Abstract] [Full Text] [Related]
11. Comparison of five beta-adrenoreceptor antagonists with different ancillary properties during sustained twice daily therapy in angina pectoris.
Thadani U; Davidson C; Singleton W; Taylor SH
Am J Med; 1980 Feb; 68(2):243-50. PubMed ID: 6101934
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of three beta 1-adrenoreceptor blocking drugs with different degree of intrinsic stimulating activity (metoprolol, practolol and H 87/07) in patients with angina pectoris.
Keyriläinen O; Uusitalo A
Ann Clin Res; 1978 Aug; 10(4):185-90. PubMed ID: 30388
[TBL] [Abstract][Full Text] [Related]
13. An eighteen months' study of the clinical response to metoprolol, a selective beta1-receptor blocking agent, in patients with angina pectoris.
Comerford MB; Besterman EM
Postgrad Med J; 1976 Aug; 52(610):481-6. PubMed ID: 10564
[TBL] [Abstract][Full Text] [Related]
14. Double-blind titrated-dose comparison of metoprolol and propranolol in the treatment of angina pectoris.
Frick MH; Luurila O
Ann Clin Res; 1976 Dec; 8(6):385-92. PubMed ID: 795362
[TBL] [Abstract][Full Text] [Related]
15. [Double-blind, placebo-controlled trial of propranolol vs celiprolol in stable effort angina: antianginal efficacy and side effects ].
Klein W; Fluch N; Brandt D
Wien Klin Wochenschr; 1982 May; 94(10):258-61. PubMed ID: 6126961
[TBL] [Abstract][Full Text] [Related]
16. [Penbutolol--a sinistrorotatory adrenergic beta-receptor blocking agent. Ergometer investigations in patients with angina pectoris].
Prahl P; Prahl M
Ugeskr Laeger; 1973 May; 135(20):965-8. PubMed ID: 4148295
[No Abstract] [Full Text] [Related]
17. Effects of cedilanid-D in combination with metoprolol on exercise tolerance and systolic time intervals in angina pectoris.
Ekelund LG; Johnsson G; Melcher A; Oro L
Am J Cardiol; 1976 Mar; 37(4):630-4. PubMed ID: 3961
[TBL] [Abstract][Full Text] [Related]
18. Effects of bevantolol and atenolol on symptoms, exercise tolerance and metabolic risk factors in angina pectoris.
Salonen JT; Taskinen E; Salonen R; Seppänen K; Venäläinen J; Rauramaa R
Am J Cardiol; 1986 Nov; 58(12):35E-40E. PubMed ID: 2878600
[TBL] [Abstract][Full Text] [Related]
19. Clinical trial of a new beta-receptor blocking agent, tolamolol, in angina pectoris.
Nordenfelt I; Olsson L; Persson S
Eur J Clin Pharmacol; 1974; 7(3):157-62. PubMed ID: 4152812
[No Abstract] [Full Text] [Related]
20. Double-blind comparison of tolamolol, propranolol, practolol, and placebo in the treatment of angina pectoris.
Jackson G; Atkinson L; Oram S
Br Med J; 1975 Mar; 1(5960):708-12. PubMed ID: 804952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
